|
RFS Pharma, LLC Acquisition (Details) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2014
|
|---|---|
| Business Combinations [Abstract] | |
| Purchased in-process research and development | $ 184,966cocp_BusinessCombinationResearchAndDevelopmentInProcess |
| Net book value of tangible assets acquired | (182)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialAssets |
| Goodwill | 65,195us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet |
| Deferred tax liability | (65,195)us-gaap_DeferredCreditsAndOtherLiabilities |
| Total purchase price | $ 184,784us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments |
| X | ||||||||||
|
- Definition
custom:BusinessCombinationResearchAndDevelopmentInProcess No definition available.
|
| X | ||||||||||
|
- Definition
Total remaining unamortized or unaccreted amounts of premiums, discounts, and intangible assets, in years subsequent to the year of acquisition, when the total amounts of remaining discounts, premiums, and intangible assets exceed 30 percent of stockholders' equity. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of financial assets (as defined) recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities). No definition available.
|